{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:28Z","timestamp":1740144208955,"version":"3.37.3"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Medical and Health Research Fund Project","award":["2018KY171"],"award-info":[{"award-number":["2018KY171"]}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"crossref","award":["2018C37104"],"award-info":[{"award-number":["2018C37104"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Medical and Health Research Fund Project","award":["2018KY818"],"award-info":[{"award-number":["2018KY818"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Brain metastasis (BM) is a serious complication in non-small cell lung cancer (NSCLC) patients. Pemetrexed is one of the preferred agents in nonsquamous NSCLC with BM; however, the traditional chemotherapy demonstrated limited efficacy partly due to drug resistance and the blood-brain barrier.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 52-year-old male non-smoker was admitted for irritating cough, chest distress, and back pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Epidermal growth factor receptor wild-type, anaplastic lymphoma kinase-negative primary lung adenocarcinoma with an asymptomatic solitary BM (cTxNxM1b, IVA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Pemetrexed (500\u200amg\/m<jats:sup>2<\/jats:sup> of body surface area) and carboplatin (area under the curve of 5) were firstly administered every 3 weeks for 3 cycles, followed by pemetrexed\/carboplatin plus anlotinib (12\u200amg daily; 2 weeks on and 1 week off) for another 3 cycles. Then maintenance anlotinib monotherapy was continued for a year, without unacceptable adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The BM was slightly enlarged after 3 cycles of pemetrexed\/carboplatin; however, a complete remission was achieved after the combination therapy. His intracranial progression-free survival was more than 2 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Pemetrexed\/carboplatin plus anlotinib could be considered for the treatment of epidermal growth factor receptor wild-type, anaplastic lymphoma kinase-negative lung adenocarcinoma with BM. Further well-designed trials are warranted to verify this occasional finding.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022128","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T14:21:31Z","timestamp":1598970091000},"page":"e22128","source":"Crossref","is-referenced-by-count":4,"title":["First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis"],"prefix":"10.1097","volume":"99","author":[{"given":"Chu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Wei","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Xuzhou Infectious Disease Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respirology and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respirology and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Mao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respirology and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7273-0358","authenticated-orcid":false,"given":"Yuan-Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respirology and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: first global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"R2-20230915","first-page":"36","article-title":"China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy","volume":"39","author":"Zhou","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"(Suppl 6)","key":"R6-20230915","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.21037\/atm.2019.07.02","article-title":"The 8(th) UICC\/AJCC TNM edition for non-small cell lung cancer staging: getting off to a flying start?","volume":"7","author":"Lancia","year":"2019","journal-title":"Ann Transl Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11864-019-0649-y","article-title":"Precision medical approaches to the diagnoses and management of brain metastases","volume":"20","author":"Chukwueke","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"(Suppl 1)","key":"R8-20230915","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.3747\/co.25.3733","article-title":"Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?","volume":"25","author":"Abdallah","year":"2018","journal-title":"Curr Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000493057","article-title":"Targeted therapies for brain metastases","volume":"34","author":"Niranjan","year":"2019","journal-title":"Prog Neurol Surg"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/jpet.105.090043","article-title":"Distribution of the novel antifolate pemetrexed to the brain","volume":"315","author":"Dai","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11060-013-1055-0","article-title":"Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases","volume":"112","author":"Kumthekar","year":"2013","journal-title":"J Neurooncol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","article-title":"Brain metastasis","volume":"20","author":"Boire","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"e13014","DOI":"10.1097\/MD.0000000000013014","article-title":"Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: a single institution retrospective analysis","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/EDBK_241345","article-title":"Modern management of central nervous system metastases in the era of targeted therapy and immune oncology","volume":"39","author":"Brastianos","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R16-20230915","first-page":"267","article-title":"Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis","volume":"22","author":"Balasubramanian","year":"2020","journal-title":"Neuro Oncol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.canrad.2019.03.009","article-title":"Management of CNS disease in ALK-positive non-small cell lung cancer: is whole brain radiotherapy still needed?","volume":"23","author":"Wrona","year":"2019","journal-title":"Cancer Radiother"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"219","DOI":"10.21037\/jtd.2017.12.30","article-title":"A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy","volume":"10","author":"Gubens","year":"2018","journal-title":"J Thorac Dis"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lungcan.2009.03.019","article-title":"Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung","volume":"65","author":"Omlin","year":"2009","journal-title":"Lung Cancer"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","article-title":"Activity of pemetrexed on brain metastases from non-small cell lung cancer","volume":"68","author":"Bearz","year":"2010","journal-title":"Lung Cancer"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/neuonc\/nos004","article-title":"Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma","volume":"14","author":"Bailon","year":"2012","journal-title":"Neuro Oncol"},{"key":"R23-20230915","first-page":"793","article-title":"Long-term survival of patient with brain metastases from lung cancer treated by pemetrexed monotherapy","volume":"39","author":"Ito","year":"2012","journal-title":"Gan To Kagaku Ryoho"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/1477-7819-10-235","article-title":"Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib","volume":"10","author":"Yuan","year":"2012","journal-title":"World J Surg Oncol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3892\/ol.2012.888","article-title":"Efficacy assessment of pemetrexed treatment of an NSCLC case with brain metastasis","volume":"4","author":"Liang","year":"2012","journal-title":"Oncol Lett"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2012.12.010","article-title":"Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases","volume":"80","author":"Ochi","year":"2013","journal-title":"Lung Cancer"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3892\/mco.2014.256","article-title":"Erlotinib with pemetrexed\/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases","volume":"2","author":"Zhang","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1179\/1973947815Y.0000000005","article-title":"Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study","volume":"27","author":"Zhu","year":"2015","journal-title":"J Chemother"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/pme.15.25","article-title":"Efficacy of pemetrexed in a patient with brain metastases during crizotinib treatment","volume":"12","author":"Zhang","year":"2015","journal-title":"Per Med"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2147\/OTT.S102236","article-title":"Comparison of erlotinib and pemetrexed as second-\/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases","volume":"9","author":"He","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"e4401","DOI":"10.1097\/MD.0000000000004401","article-title":"Pemetrexed\/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: a case report and literature review","volume":"95","author":"He","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.3892\/ol.2016.5268","article-title":"Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: focus on patients with brain metastases","volume":"12","author":"Stefanou","year":"2016","journal-title":"Oncol Lett"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.2147\/CMAR.S222910","article-title":"Bevacizumab in combination with pemetrexed and platinum significantly improved the clinical outcome of patients with advanced adenocarcinoma NSCLC and brain metastases","volume":"11","author":"Tian","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"e14110","DOI":"10.1097\/MD.0000000000014110","article-title":"Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status","volume":"98","author":"Yu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"18689","DOI":"10.1038\/s41598-019-55150-6","article-title":"The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: a retrospective nationwide population-based cohort study","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:12:21Z","timestamp":1694826741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022128"}},"subtitle":["A case report and review of the literature"],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":35,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022128","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}